Osteosarcoma and Other Neoplasms of Bone

Ross, Brian D.; Helsper, James T.; Cox, I. Jane; Young, I. R.; Kempf, Raymond A.; Makepeace, Andrew; Pennock, J. M.

doi:10.1001/archsurg.1987.01400240112021

Cited by 44 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While tumor PCr content, as observed in this study, was less than that of normal muscle (P < 0.01 ) it varied from 13 to 43%. Considerable variability in PCr peak intensities of human tumors in situ has also been observed by a number of other research groups (8,9 ) .…”

Section: Discussionmentioning

confidence: 57%

“…Spectral changes postchemotherapy have been observed by a number of groups (8,9,11,(13)(14)(15)(16), but how these relate to patient prognosis has not yet been firmly established. In this study, reduction in PDE levels from the initial prechemotherapy "P spectrum to the final presurgery spectrum (interval of approximately 3 months) was associated with percentage histological necrosis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Tissue characterization and assessment of preoperative chemotherapeutic response in musculoskeletal tumors by in vivo³¹p magnetic resonance spectroscopy

Om¹,

Bell²,

Jp³

et al. 1992

Magnetic Resonance in Med

View full text Add to dashboard Cite

This study investigates the potential of in vivo 31P magnetic resonance spectroscopy (MRS) to characterize musculoskeletal tumors and to determine preoperative levels of histological necrosis, which is an important clinical indicator of patient response. Pretherapy MRS was performed on 28 patients with large musculoskeletal tumors: 13 with osteosarcoma, 3 with chondrosarcoma, 5 with malignant fibrous histiocytoma, 1 with desmoid tumor, 1 with Ewing's, 2 with hemangioendothelioma, 1 with myxoid liposarcoma, 1 with synovial cell sarcoma, and 1 with rhabdomyosarcoma. Fifteen patients had follow-up MRS examinations after commencement of chemotherapy (mean of five/patient), eight of whom have now had surgery. Elevated levels of PMEs (P < 0.01), P(i) (P < 0.01), and PDEs (P < 0.02) as well as elevated tumor pH (P < 0.05) were observed in all patients. The synovial cell sarcoma was characterized by high levels of PMEs (> 20%) and low pH (pH 6.76). This contrasted with the spectra obtained from the malignant fibrous histiocytomas which had high levels of PDEs (17 +/- 5%). Reductions in PDE levels postchemotherapy were associated with a high degree of necrosis (> 90%) at surgery, while an increase in PDE levels was associated with a low level of histological necrosis. Likewise, reductions in the ratios PDE/NTP and PDE/PCr and an increase in P(i)/PDE were also associated with a high level of necrosis.

show abstract

Section: Discussionmentioning

confidence: 57%

Section: Discussionmentioning

confidence: 99%

Tissue characterization and assessment of preoperative chemotherapeutic response in musculoskeletal tumors by in vivo³¹p magnetic resonance spectroscopy

Om¹,

Bell²,

Jp³

et al. 1992

Magnetic Resonance in Med

View full text Add to dashboard Cite

show abstract

“…The information derived from these animal studies suggests that NMR spectroscopy might be useful for predicting tumor response to chemotherapy. Recently, this technique has been applied to clinical studies (9)(10)(11)(12)(13)(14)(15)(16)(17)(18) as a potential early predictor of tumor response.…”

Section: Introductionmentioning

confidence: 99%

“…Ross et al have studied 14 patients with bone tumors ( 9 ) . They noted that their spectra did not resemble that of normal muscle because of the presence of significant phosphodiester ( PDE) and phosphomonoester (PME ) peaks and different proportions of nucleotide triphosphate (NTP) and phosphocreatine (PCr) .…”

Section: Introductionmentioning

confidence: 99%

³¹P NMR spectra of extremity sarcomas: Diversity of metabolic profiles and changes in response to chemotherapy

Koutcher

Ballon

Graham

et al. 1990

Magnetic Resonance in Med

View full text Add to dashboard Cite

We have used 31P NMR spectroscopy to study 22 patients with suspected sarcomas prior to any treatment. The spectra are characterized by the same peaks noted in murine tumors. The mean pH was 7.14 +/- 0.08 and PCr/Pi was 1.18 +/- 0.83. Comparison of pH and PCr/Pi ratios in human and a murine tumor with a low hypoxic cell fraction revealed no significant differences. Six patients subsequently received chemotherapy and three responded to therapy (based on pathologic examination and/or tumor reduction greater than 50%). The three responding patients were noted to have significantly lower PDE/PME in their pretreatment spectra than the three nonresponding patients. The three responding patients with sarcomas also showed a rise of greater than 100% in PDE/PME during the first cycle of therapy. Two of the responding patients had an increase of 0.37 pH units during this interval, which was not detected in the nonresponding patients. These data suggest that 31P NMR spectroscopy may be a useful prognostic indicator in conjunction with other clinical parameters.

show abstract

“…Because they are typically localized to the extremities, osteosarcomas in the clinical setting are amenable to MR interrogation via surface coil with resulting benefits in terms of measurement sensitivity (36). The feasibility of obtaining well-defined MR spectra from bone tumors was initially unclear, but Nidecker et al did 31 P MR spectroscopic measurements of bone tumors (37) and later studies showed that 31 P MR-observable tumor metabolic variables observed as little as 2 days post-therapy correlated with therapeutic response to chemotherapy (38).…”

Section: Discussionmentioning

confidence: 99%

An 19F Magnetic Resonance–Based In Vivo Assay of Solid Tumor Methotrexate Resistance: Proof of Principle

Spees¹,

Gade²,

Yang

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Studies in oncology have implicated multiple molecular mechanisms as contributors to intrinsic and acquired tumor resistance to antifolate therapy. Here we show the utility of an 19 F-labeled methotrexate (FMTX) with 19 F magnetic resonance to differentiate between sensitive and resistant tumors in vivo and thus predict therapeutic response.Experimental Design: Human sarcoma xenografts in nude mice were used in this study. The sarcoma cell lines chosen for this study (HT-1080, HS-16, and M-805) are well characterized in terms of their methotrexate sensitivity and molecular mechanisms of resistance. The pharmacokinetics of tumor uptake/washout of FMTX were monitored via in vivo 19 F magnetic resonance spectroscopy (pulse/acquire with surface coil localization) following an i.v. bolus injection. Response post-therapy, following leucovorin rescue, was monitored via tumor growth.Results: The three tumor models show differences in both the peak concentrations of tumor FMTX and the dynamics of uptake/retention. These differences are most pronounced for time points late in the magnetic resonance observation period (225-279 minutes post-injection). A statistically significant linear correlation between tumor tissue concentrations of FMTX at these late time points and therapeutic response in the days/weeks post-treatment is shown (R = 0.81, F = 9.27, P < 0.001). Interestingly, a 400 mg/kg i.v. bolus injection of FMTX is a more potent cytotoxic agent in vivo against methotrexate-sensitive tumors than is the parent compound (P = 0.011).Conclusions: In principle, the assay method described herein could be implemented in the clinic as a diagnostic tool to make decisions regarding therapeutic protocol for the treatment of osteosarcoma on a case-by-case basis.

show abstract

Osteosarcoma and Other Neoplasms of Bone

Cited by 44 publications

References 5 publications

Tissue characterization and assessment of preoperative chemotherapeutic response in musculoskeletal tumors by in vivo³¹p magnetic resonance spectroscopy

Tissue characterization and assessment of preoperative chemotherapeutic response in musculoskeletal tumors by in vivo³¹p magnetic resonance spectroscopy

³¹P NMR spectra of extremity sarcomas: Diversity of metabolic profiles and changes in response to chemotherapy

An 19F Magnetic Resonance–Based In Vivo Assay of Solid Tumor Methotrexate Resistance: Proof of Principle

Contact Info

Product

Resources

About

Osteosarcoma and Other Neoplasms of Bone

Cited by 44 publications

References 5 publications

Tissue characterization and assessment of preoperative chemotherapeutic response in musculoskeletal tumors by in vivo31p magnetic resonance spectroscopy

Tissue characterization and assessment of preoperative chemotherapeutic response in musculoskeletal tumors by in vivo31p magnetic resonance spectroscopy

31P NMR spectra of extremity sarcomas: Diversity of metabolic profiles and changes in response to chemotherapy

An 19F Magnetic Resonance–Based In Vivo Assay of Solid Tumor Methotrexate Resistance: Proof of Principle

Contact Info

Product

Resources

About

Tissue characterization and assessment of preoperative chemotherapeutic response in musculoskeletal tumors by in vivo³¹p magnetic resonance spectroscopy

Tissue characterization and assessment of preoperative chemotherapeutic response in musculoskeletal tumors by in vivo³¹p magnetic resonance spectroscopy

³¹P NMR spectra of extremity sarcomas: Diversity of metabolic profiles and changes in response to chemotherapy